Search

Search Constraints

You searched for: Author/Creator Pierce, Amy

Search Results

1. 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. (4th December 2021)

2. 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. (4th December 2021)

4. Healthcare-associated outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in a rural hospital in Missouri, March 2020. (20th November 2021)

5. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. (1st June 2021)

6. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. (February 2021)

7. Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Issue 1 (9th December 2021)

8. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Issue 11 (November 2020)